Stoney! Hey when you made this post, CHWY was $27.70 pre-market When you made this one it was $26 and change: I only mention this because its $27.70 now. Save us the "+17%, this is why GBA is number one". CHWY $27.70
It's also been in the top 3 "most mentioned stocks" on Wall Street Bets for over a week fwiw. Everyone was on Chwy at its lifetime low the last few weeks. Imax was all the buzz too.
HUGE HEATH BREAKTHROUGH-! https://www.nbcnews.com/health/heal...rimental-approach-shrank-tumors-one-rcna31437 A woman with pancreatic cancer has been cured for now. T-Cell therapy targeting KRAS G12D. This is the new breakthrough! SQZ Bio which we just had the other day as a gummy may play a roll here... I'm looking into it- I see some applications. Mirati has had some set backs but are in the game.. Amgen is working on this. Mirati had a so so outcome on their product and MRTX stock crashed last week 31.9% to 39.81.<------ Watch Today) MRTX & SQZ <-------------- Saudi ready to pump more crude to make up for lack of Russia oil. Oil DOWN.> Ocugen initiated with an Overweight at Cantor Fitzgerald 06:45 OCGN Cantor Fitzgerald analyst… Piper ups Repare Therapeutics target after 'great deal' with Roche 06:35 RPTX, RHHBY Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Repare Therapeutics (RPTX) to $30 from $25 and keeps an Overweight rating on the shares after the company entered into a license agreement with Roche (RHHBY) for its ATR inhibitor camonsertib. The deal provides Repare with a $125M upfront payment, the potential of $1.2B in milestones, and the ability to opt-in to 50/50 U.S. co-development and profit share, Catanzaro tells investors in a research note. The analyst views this as a "great deal" for Repare, saying it allows the potential utility to camonsertib to be fully explored, while unloading the development costs, but still having the ability to participate in the longer-term potential upside. Repare now has cash into 2026 and can "aggressively move forward with the rest of its novel and growing precision oncology pipeline," contends the anlayst. RPTX <----- OCGN - RPTX - UiPath up 7.8% at $18.14 after Q1 earnings beat, FY23 guidance raise 16:51 PATH Phillips 66 VP Herman sells almost $4.9M in company shares 17:34 PSX Phillips 66 VP Robert Herman disclosed in a filing that he had sold 47,200 shares of company stock at $102.82 per share on May 31, for a total transaction amount of 4,853,279.<----- THE CHILDREN WILL EAT WELL TONIGHT-! Chewy reports Q1 Active Customers up 4.2% y/y at 20.6M 16:11 CHWY Reports Q1 Net Sales per Customer $446, up 14.9% y/y. Chewy jumps 20% to $28.09 after Q1 profit beats estimates 16:38 CHWY <----- Pure Storage jumps 10% to $26.40 after Q1 results, FY23 guidance beat estimates 16:12 PSTG Pure Storage raises FY23 revenue view to $2.66B from $2.6B, consensus $2.59B 16:10 PSTG <-------- Oppenheimer upgrades Wolfspeed to Outperform with $105 price target 06:48 WOLF, SEDG As previously reported, Oppenheimer analyst Colin Rusch upgraded Wolfspeed (WOLF) to Outperform from Perform with a $105 price target as he finds it demonstrating a highly defensible technology position poised for outsized growth despite trading at levels with compelling risk/reward profiles. While the analyst expects some inefficiency in Wolfspeed's Mohawk Valley ramp, the company should work through any yield issues in an expedited manner, resulting in steady margin improvement. Rusch also believes Wolfspeed is effectively leveraging SiC wafer and epitaxy capabilities into device wins. This mix shift should increase the revenue potential on current facilities to $2.7B-plus on this footprint, he adds. <---- Blue Apron jumps 19.5% to $3.67 after entering distribution deal on Walmart.com 16:30 APRN Proterra initiated with a Buy at DA Davidson 16:21 PTRA DA Davidson analyst Michael Shlisky initiated coverage of Proterra with a Buy rating and $10 price target. He views investing in Proterra "like an investment in a subset of pre-vetted, quality EV-truck companies," said Shlisky, who thinks Proterra is emerging as a preferred provider of batteries to electric truck makers. Desktop Metal management to meet with Benchmark 14:33 DM Meeting to be held in Burlington, MA on June 9 hosted by Benchmark. BIOTECH KRAS biotech Mirati delivers so-so news for investors closely watching Amgen battle ByAnnalee ArmstrongMay 7, 2021 12:28pm
Van I gave out this name several times and it dived after I gave it the day before earn and and the Children got in a $24!!! <--- You could have as well if you opened your heart.... I gave the children a better price than me-- Who Else does that. NOBODY! $$$$$$$$$$$$$$$$$$$ GBA #1 FOR A REASON $$$$$$$$$$$$$$$$$$$ I'M ON QUITE A ROLL WITH THESE EARNINGS REPORTS! ZOOM, SNOW,AIRBNB, CHWY WHEN DOES IT STOP! INCREDIBLE!4-4
Know what's interesting about Chewy, about 25% of the float is short, or was as of May 13th. It was $27 then too. Then it got down to $22 and bounced back to $27 over 7 trading days. Then it drops from $27 to $23 yesterday on heavy volume. Now its $28 pre-market. Hmmmm. Odd behavior. Stoney, if it spikes above $29 today, take it and we'll get back in later.
---SQM Whilst it may not be a huge deal, we thought it was good to see that the SQZ Biotechnologies Company(NYSE:SQZ) Independent Director, Klavs Jensen, recently bought US$50k worth of stock, for US$3.52 per share. Although the purchase is not a big one, increasing their shareholding by only 4.2%, it can be interpreted as a good sign. The Last 12 Months Of Insider Transactions At SQZ Biotechnologies Notably, that recent purchase by Klavs Jensen is the biggest insider purchase of SQZ Biotechnologies shares that we've seen in the last year. That implies that an insider found the current price of US$3.55 per share // SQZ -6.48% In the last twelve months SQZ Biotechnologies insiders were buying shares, but not selling. Their average price was about US$5.04. /////////// insider-trading-volume Wed, June 1, 2022, 4:45 PM In this article: SQZ -6.48% WATERTOWN, Mass., June 01, 2022--(BUSINESS WIRE)--SQZ Biotechnologies(NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on June 8, in New York, NY. Presentation time and webcast information is available below. PRESENTATION DETAILS Wednesday, June 8 Jefferies Healthcare Conference 2:30-2:55 p.m. ET ImportANT abstrAct... FOLKS YOU ARE GETTING THE FULL STONEY BIO TREATMENT HERE-! https://s26.q4cdn.com/867116262/files/AACR-2021-PBMC-KRas-Poster-C.-Smith-FINAL.pdf SQM has developed cell squeeze<----- Abstract KRAS mutations are shared across multiple cancer types and are most commonly found in cancers of the lung, pancreas, and colon. While recently developed drugs blocking signaling driven by KRAS G12C mutations have shown promise in the clinic, there is a great need for therapies targeting the more common G12V and G12D mutations that are not easily targeted with small molecules. We utilize our microfluidic Cell Squeeze®<----------------------- STOCK OF THE DAY SQM--------
Repare Therapeutics Inc. (RPTX) 8.75-0.43(-4.68%) At close: June 1 04:00PM EDT 10.90+2.15(+24.57%)<---------- Pre-Market:8:02AM EDT
Conditions for a global stock meltdown have been met, research firm says Jun. 02, The five pillars of global financial stability are faltering dangerously, according to quant research shop Gavekal-IS. Currently, "the conditions for a global equity crash are met," Gavekal said in a note. "No prophecy here, simply the observation of riskstates." The five pillars areworld dollar liquidity, energy costs, international trade, inflation and fear. Looking at them separately: World liquidity in U.S. dollars contracting fast The MSCI World index (URTH) returned -2% cash per annum in liquidity contraction times vs. cash +135% in expansion, they said.. U.S. energy costs spiking at uncharted levels Gavekal's U.S. Primary Energy Index rose by 150% in the last 12 months, the highest inflation in 120 years. Global trade is severely damaged The Dow Transportation Index (DJT) (IYT) is a good proxy for international trade and is at its lowest leve in seven months. When "it reaches new highs, US and global equity markets follow," they said. Inflation has diffused globally Gavekal's Inflation Index tracks 40 countries with a range of 0% (no countries with inflation) to 100% (all countries). It now stands at 100% for the second time in 50 years, the last being September 2008. Fear Index similar to 'dangerous' periods Gavekal's Fear Diffusion Index, a measure of equity tail risks exhibited in 40 different markets, is now 70% on a scale of 0% to 100% (see chart at bottom). "The Fear Index is a warning that equity markets are ready to amplify bad news if they occur, not that bad news will occur." In deperate times, strong leaders have been able to turn situations around, but international leaders are weakened by domestic concerns, Gavekal added. "The chances of a strong and coordinated international leadership to set things straight do not look promising." See why JPMorgan strategist Marko Kolanovic argues for asecond-half stock rebound.
Nasdaq, S&P, Dow futures point to rebound after Hurricane Dimon jolt POOR JAMIE ... I THINK HE SPOKE OFF THE CUFF A BIT... I WOULD ADD HURRICANE'S SCARY AS THEY ARE OFTEN SPIN RIGHT OUT TO SEA WITHOUT AFFECTING LAND....